Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F.

Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15.

PMID:
26385265
2.

Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.

Ohri N, Tomé W, Kalnicki S, Garg M.

Pract Radiat Oncol. 2018 Mar - Apr;8(2):e33-e39. doi: 10.1016/j.prro.2017.10.002. Epub 2017 Oct 7.

PMID:
29233523
3.

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.

Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, Muacevic A, Mahadevan A.

Radiat Oncol. 2015 May 15;10:113. doi: 10.1186/s13014-015-0417-5.

4.

Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.

Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M.

Radiother Oncol. 2013 Oct;109(1):13-20. doi: 10.1016/j.radonc.2013.09.005. Epub 2013 Oct 30.

PMID:
24183066
5.

Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.

Huang BT, Lin Z, Lin PX, Lu JY, Chen CZ.

Oncotarget. 2016 Jun 28;7(26):40746-40755. doi: 10.18632/oncotarget.9442.

6.
7.

Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.

Liang X, Penagaricano J, Zheng D, Morrill S, Zhang X, Corry P, Griffin RJ, Han EY, Hardee M, Ratanatharathom V.

Radiat Oncol. 2016 Jan 22;11:10. doi: 10.1186/s13014-015-0578-2.

8.

Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".

Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, Blanck O, Wittig A, Boda-Heggemann J, Krempien R, Lohaus F, Klass ND, Eble MJ, Imhoff D, Kahl H, Petersen C, Gerum S, Henkenberens C, Adebahr S, Hass P, Schrade E, Wendt TG, Hildebrandt G, Andratschke N, Sterzing F, Guckenberger M.

Lung Cancer. 2016 Jul;97:51-8. doi: 10.1016/j.lungcan.2016.04.012. Epub 2016 Apr 26.

PMID:
27237028
9.

Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.

Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, Richter A, Wilbert J, Flentje M.

Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):47-54. doi: 10.1016/j.ijrobp.2008.06.1939. Epub 2008 Oct 30.

PMID:
18977095
10.

Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Liu F, Tai A, Lee P, Biswas T, Ding GX, El Naqa I, Grimm J, Jackson A, Kong FS, LaCouture T, Loo B Jr, Miften M, Solberg T, Li XA.

Radiother Oncol. 2017 Feb;122(2):286-294. doi: 10.1016/j.radonc.2016.11.006. Epub 2016 Nov 18. Review.

11.

Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.

Ohri N, Werner-Wasik M, Grills IS, Belderbos J, Hope A, Yan D, Kestin LL, Guckenberger M, Sonke JJ, Bissonnette JP, Xiao Y.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e379-84. doi: 10.1016/j.ijrobp.2012.04.040.

12.

Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.

Salazar OM, Sandhu TS, Lattin PB, Chang JH, Lee CK, Groshko GA, Lattin CJ.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):707-15. doi: 10.1016/j.ijrobp.2008.01.054. Epub 2008 May 1.

PMID:
18455322
13.

Single institution experience treating adrenal metastases with stereotactic body radiation therapy.

Shah MM, Isrow D, Fareed MM, Wen N, Ryu S, Ajlouni M, Siddiqui F.

J Cancer Res Ther. 2019 Mar;15(Supplement):S27-S32. doi: 10.4103/jcrt.JCRT_655_16.

14.

Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Guckenberger M, Klement RJ, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Xiao Y, Grills IS.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1074-81. doi: 10.1016/j.ijrobp.2012.09.016. Epub 2012 Nov 12.

PMID:
23154077
15.

Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases.

Fritz P, Kraus HJ, Mühlnickel W, Hammer U, Dölken W, Engel-Riedel W, Chemaissani A, Stoelben E.

Radiat Oncol. 2006 Aug 20;1:30.

16.

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.

Repka MC, Aghdam N, Kataria SK, Campbell L, Suy S, Collins SP, Anderson E, Lischalk JW, Collins BT.

Radiat Oncol. 2017 Oct 19;12(1):162. doi: 10.1186/s13014-017-0897-6.

17.

Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.

Tembhekar AR, Wright CL, Daly ME.

Clin Lung Cancer. 2017 May;18(3):293-298. doi: 10.1016/j.cllc.2016.12.007. Epub 2016 Dec 22.

18.

Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.

Kelley KD, Benninghoff DL, Stein JS, Li JZ, Byrnes RT, Potters L, Knisely JP, Zinkin HD.

Radiat Oncol. 2015 May 28;10:120. doi: 10.1186/s13014-015-0423-7.

19.

Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.

Bhandari RP, Stanford JD, Packianathan S, Duggar WN, Kanakamedala MR, Zhang X, Giri SP, Kumar PP, Harrell LM, Mangana SH, Yang C, Vijayakumar S.

Oncology. 2016;91(4):194-204. Epub 2016 Jul 19.

PMID:
27427761
20.

Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.

Katoh N, Soda I, Tamamura H, Takahashi S, Uchinami Y, Ishiyama H, Ota K, Inoue T, Onimaru R, Shibuya K, Hayakawa K, Shirato H.

Radiat Oncol. 2017 Jan 5;12(1):3. doi: 10.1186/s13014-016-0742-3.

Supplemental Content

Support Center